Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

被引：6
|
作者：
Liu, Joyce F.
Barry, William Thomas
Birrer, Michael J.
Lee, Jung-min
Buckanovich, Ronald J.
Fleming, Gini F.
Rimel, B. J.
Buss, Mary K.
Nattam, Sreenivasa R.
Hurteau, Jean
Luo, Weixiu
Farooq, Sarah
Whalen, Christin
Kohn, Elise C.
Ivy, S. Percy
Matulonis, Ursula A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5535
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
    Liu, J. F.
    Barry, W. T.
    Birrer, M.
    Lee, J-M
    Buckanovich, R. J.
    Fleming, G. F.
    Rimel, B. J.
    Buss, M. K.
    Nattam, S. R.
    Hurteau, J.
    Luo, W.
    Curtis, J.
    Whalen, C.
    Kohn, E. C.
    Ivy, S. P.
    Matulonis, U. A.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 551 - 557
  • [2] A randomized phase 2 trial comparing efficacy of the combination of the PAR? inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
    Liu, Joyce
    Barry, William Thomas
    Birrer, Michael J.
    Lee, Jung-min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa R.
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Obermayer, Elizabeth
    Whalen, Christin
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
    Liu, Joyce
    Barry, William Thomas
    Birrer, Michael J.
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rime, Bj
    Buss, Mary K.
    Natiam, Sreenivasa R.
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Obermayer, Elizabeth
    Whalen, Christin
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [4] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    Liu, Joyce F.
    Barry, William T.
    Birrer, Michael
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Whalen, Christin
    Obermayer, Lisa
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    LANCET ONCOLOGY, 2014, 15 (11): : 1207 - 1214
  • [5] A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
    Liu, Joyce F.
    Brady, Mark F.
    Matulonis, Ursula A.
    Miller, Austin
    Kohn, Elise C.
    Swisher, Elizabeth M.
    Tew, William P.
    Cloven, Noelle Gillette
    Muller, Carolyn
    Bender, David
    Moore, Richard G.
    Michelin, David Paul
    Waggoner, Steven E.
    Geller, Melissa Ann
    Fujiwara, Keiichi
    D'Andre, Stacy D.
    Carney, Michael
    Secord, Angeles Alvarez
    Moxley, Katherine M.
    Bookman, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer
    Lee, Jung-Min
    Trepel, Jane B.
    Choyke, Peter
    Cao, Liang
    Sissung, Tristan
    Houston, Nicole
    Yu, Minshu
    Figg, William D.
    Turkbey, Ismail Baris
    Steinberg, Seth M.
    Lee, Min-Jung
    Ivy, S. Percy
    Liu, Joyce F.
    Matulonis, Ursula A.
    Kohn, Elise C.
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [7] Treatment with Maintenance Olaparib Significantly Improves Progression-Free Survival in Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Results of SOLO2 Study
    Friedlander, M.
    Pujade-Lauraine, E.
    Ledermann, J. A.
    Penson, R. T.
    Oza, A. M.
    Korach, J.
    Huzarski, T.
    Poveda, A.
    Pignata, S.
    Colombo, N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 51 - 51
  • [8] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Oza, Amit M.
    Cibula, David
    Oaknin Benzaquen, Ana
    Poole, Christopher
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Holger
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Lowe, Elizabeth S.
    Dougherty, Brian
    Barrett, J. Carl
    Friedlander, Michael
    LANCET ONCOLOGY, 2015, 16 (01): : 87 - 97
  • [9] Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
    Tjokrowidjaja, Angelina
    Friedlander, Michael
    Lord, Sarah J.
    Asher, Rebecca
    Rodrigues, Manuel
    Ledermann, Jonathan A.
    Matulonis, Ursula A.
    Oza, Amit M.
    Bruchim, Ilan
    Huzarski, Tomasz
    Gourley, Charlie
    Harter, Philipp
    Vergote, Ignace
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Milenkova, Tsveta
    Pujade-Lauraine, Eric
    Gebski, Val
    Lee, Chee K.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 190 - 200
  • [10] Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
    C K Lee
    R J Simes
    C Brown
    S Lord
    U Wagner
    M Plante
    I Vergote
    C Pisano
    G Parma
    A Burges
    H Bourgeois
    T Högberg
    J Bentley
    L Angleitner-Boubenizek
    A Ferrero
    B Richter
    H Hirte
    V Gebski
    J Pfisterer
    E Pujade-Lauraine
    M Friedlander
    British Journal of Cancer, 2011, 105 : 1144 - 1150
12345